Cancer patients who self-report symptoms to their doctors on a weekly basis live five months longer
A provocative study at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting reported that metastatic cancer patients who self-reported their symptoms to their doctors on a weekly basis...Read More
Abiraterone and Enzalutamide equivalent as first-line therapy in metastatic hormone therapy- resistant prostate cancer
A clinical trial reported on at the 2017 American Society of Clinical Oncology (ACSO) Annual Meeting found that men who develop metastatic hormone therapy-resistant prostate cancer (mHRPC) have similar outcomes...Read More
Your Best Weapon Against Metastatic Prostate Cancer May Be a Genetic Counselor
Mark Meerschaert is alive today because of a genetic counselor, a medical oncologist in Seattle named Heather Cheng, M.D., Ph.D. (You can read more about Mark’s story here.) Less than...Read More
Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival
ASCO Perspective “For men who are diagnosed with advanced prostate cancer, treatment has evolved into more effective approaches, first with chemotherapy and now with abiraterone,” said Sumanta Kumar Pal, MD,...Read More
2017 ASCO Meeting: Results from the LATITUDE Study
If you have just been diagnosed with metastatic prostate cancer and your doctor wants to start you on ADT (androgen deprivation therapy, such as Lupron), which shuts off the supply...Read More
Prostate Cancer Foundation and Major League Baseball Launch Annual Home Run Challenge to Defeat Prostate Cancer
LOS ANGELES, June 1, 2017 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) and Major League Baseball (MLB) are launching the annual Home Run Challenge on June 1, and running through...Read More
FDA approves first precision medicine for the treatment of cancers with certain genetic defects, including prostate cancer
On May 23, 2017, the field of precision medicine achieved a major milestone with the FDA’s first ever approval of a cancer therapy based entirely on a tumor’s unique characteristics...Read More
Prostate cancer cells that commit identify fraud
A new study reported at the 2017 American Association for Cancer Research (AACR) Annual Meeting identified new mechanisms and treatment approach for an aggressive subtype of AR-therapy resistant prostate cancer....Read More
Many vs Cancer, the First Major Global Crowdfunding Initiative to Defeat Prostate Cancer, Launches Today
LOS ANGELES, May 17, 2017 /PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the launch of Many vs Cancer (MvC), its first global fundraising initiative that is harnessing the...Read More
Study finds genetic difference in prostate cancer in African-Americans
Dana-Farber Cancer Institute News Release May 17,2017 The genomic discovery may partly explain why prostate cancer is more aggressive in black men Scientists say more blacks and other under-represented groups...Read More